SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 14, 2003; DOI 10.1182/blood-2003-02-0542. This Article Full Text (PDF) All Versions of this Article: 2003-02-0542v1 102/13/4284    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tilly, H. Articles by Reyes, F. Search for Related Content PubMed PubMed Citation Articles by Tilly, H. Articles by Reyes, F. Social Bookmarking                   What's this? Submitted February 19, 2003 Accepted July 28, 2003 Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma Herve Tilly*, Eric Lepage, Bertrand Coiffier, Michel Blanc, Raoul Herbrecht, Andre Bosly, Michel Attal, Georges Fillet, Catherine Guettier, Thierry Jo Molina, Christian Gisselbrecht, and Felix Reyes Department of Hematology, Centre Henri Becquerel, Rouen, France Department of Statistics, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Creteil, France Department of Hematology, Centre Hospitalier Lyon Sud, Pierre-Benite, France Department of Hematology, Centre Hospitalier de Chambery, Chambery, France Department of Hematology, Hopital de Hautepierre, Strasbourg, France Department of Hematology, Cliniques Universitaires de Mont Godinne, Yvoir, Belgium Department of Hematology, Hopital de Purpan, Toulouse, France Department of Hematology, Hopital Universitaire de Liege, Liege, Belgium Department of Pathology, Hopital Paul Brousse, Assistance Publique Hopitaux de Paris, Villejuif, France Department of Pathology, Hotel-Dieu, Assistance Publique Hopitaux de Paris, Paris, France Department of Hematology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris, France Department of Hematology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Creteil, France * Corresponding author; email: herve.tilly{at}rouen.fnclcc.fr. We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP with standard CHOP in previously untreated patients with poor-risk aggressive lymphoma. Patients 61 to 69 years who had aggressive non-Hodgkin's lymphoma with at least one prognostic factor of the age-adjusted IPI were included. ACVBP consisted of an induction phase of intensified chemotherapy and CNS prophylaxis followed by a sequential consolidation phase. Of the 708 patients registered for the study, 635 were eligible. The rate of complete response was 58% in the ACVBP group and 56% in the CHOP group (p=0.5). Treatment related death occurred in 13% of the ACVBP group and 7% of the CHOP group (p=0.014). At five years, the event-free survival was 39% in the ACVBP group and 29% in the CHOP group (p=0.005). The overall survival was significantly longer for patients treated with ACVBP, at 5 years it was 46% as compared with 38% for patients treated with CHOP (p=0.036). Central nervous system progressions or relapses were more frequent in the CHOP group (p=0.004). Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk aggressive lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H.A. Azim, L. Santoro, R.G. Bociek, S. Gandini, R.A. Malek, and H.A. Azim Jr High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis Ann. Onc., October 22, 2009; (2009) mdp425v1. [Abstract] [Full Text] [PDF] E. Brusamolino First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions Haematologica, September 1, 2009; 94(9): 1194 - 1198. [Full Text] [PDF] V. Boehme, N. Schmitz, S. Zeynalova, M. Loeffler, and M. Pfreundschuh CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Blood, April 23, 2009; 113(17): 3896 - 3902. [Abstract] [Full Text] [PDF] S. H. Bernstein, J. M. Unger, M. LeBlanc, J. Friedberg, T. P. Miller, and R. I. Fisher Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group J. Clin. Oncol., January 1, 2009; 27(1): 114 - 119. [Abstract] [Full Text] [PDF] M. Yamaguchi, N. Nakamura, R. Suzuki, Y. Kagami, M. Okamoto, R. Ichinohasama, T. Yoshino, J. Suzumiya, T. Murase, I. Miura, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients Haematologica, August 1, 2008; 93(8): 1195 - 1202. [Abstract] [Full Text] [PDF] S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma Ann. Onc., May 1, 2008; 19(5): 958 - 963. [Abstract] [Full Text] [PDF] N. Mourad, N. Mounier, J. Briere, E. Raffoux, A. Delmer, A. Feller, C. J. L. M. Meijer, J.-F. Emile, R. Bouabdallah, A. Bosly, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, May 1, 2008; 111(9): 4463 - 4470. [Abstract] [Full Text] [PDF] G. P. Canellos What Constitutes "Improved Prognosis"? J. Clin. Oncol., April 20, 2008; 26(12): 1913 - 1914. [Full Text] [PDF] P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2 Ann. Onc., March 1, 2008; 19(3): 560 - 565. [Abstract] [Full Text] [PDF] J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF] M Bjorkholm, H Hagberg, H Holte, S Kvaloy, L Teerenhovi, H Anderson, E Cavallin-Stahl, J Myhre, H Pertovaara, A Ost, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up Ann. Onc., June 1, 2007; 18(6): 1085 - 1089. [Abstract] [Full Text] [PDF] A. K. Ng and P. M. Mauch Role of Radiation Therapy in Localized Aggressive Lymphoma J. Clin. Oncol., March 1, 2007; 25(7): 757 - 759. [Full Text] [PDF] C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, March 1, 2007; 109(5): 2183 - 2189. [Abstract] [Full Text] [PDF] J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study Blood, December 15, 2006; 108(13): 4163 - 4169. [Abstract] [Full Text] [PDF] T. M. Habermann, E. A. Weller, V. A. Morrison, R. D. Gascoyne, P. A. Cassileth, J. B. Cohn, S. R. Dakhil, B. Woda, R. I. Fisher, B. A. Peterson, et al. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma J. Clin. Oncol., July 1, 2006; 24(19): 3121 - 3127. [Abstract] [Full Text] [PDF] N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood, May 15, 2006; 107(10): 3832 - 3840. [Abstract] [Full Text] [PDF] C. Besson, D. Canioni, E. Lepage, S. Pol, P. Morel, P. Lederlin, A. Van Hoof, H. Tilly, P. Gaulard, B. Coiffier, et al. Characteristics and Outcome of Diffuse Large B-Cell Lymphoma in Hepatitis C Virus-Positive Patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte Programs J. Clin. Oncol., February 20, 2006; 24(6): 953 - 960. [Abstract] [Full Text] [PDF] J. P. Greer Therapy of Peripheral T/NK Neoplasms Hematology, January 1, 2006; 2006(1): 331 - 337. [Abstract] [Full Text] [PDF] B. Coiffier State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6387 - 6393. [Abstract] [Full Text] [PDF] J. S. Abramson and M. A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood, August 15, 2005; 106(4): 1164 - 1174. [Abstract] [Full Text] [PDF] P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, C. Ferme, B. Christian, E. Lepage, H. Tilly, F. Morschhauser, et al. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte J. Clin. Oncol., June 20, 2005; 23(18): 4117 - 4126. [Abstract] [Full Text] [PDF] T. Tanvetyanon, M. Adli, A. Sevinc, M. E. Kalender, S. Hoecht, W. Hinkelbein, F. Reyes, and H. Tilly Treatment of Localized Lymphoma N. Engl. J. Med., June 9, 2005; 352(23): 2449 - 2451. [Full Text] [PDF] F. Reyes, E. Lepage, G. Ganem, T. J. Molina, P. Brice, B. Coiffier, P. Morel, C. Ferme, A. Bosly, P. Lederlin, et al. ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma N. Engl. J. Med., March 24, 2005; 352(12): 1197 - 1205. [Abstract] [Full Text] [PDF] U. Hegde, A. Filie, R. F. Little, J. E. Janik, N. Grant, S. M. Steinberg, K. Dunleavy, E. S. Jaffe, A. Abati, M. Stetler-Stevenson, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology Blood, January 15, 2005; 105(2): 496 - 502. [Abstract] [Full Text] [PDF] N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann. Onc., December 1, 2004; 15(12): 1790 - 1797. [Abstract] [Full Text] [PDF] C. S. Portlock, J. Qin, P. Schaindlin, N. Roistacher, J. Myers, D. Filippa, D. Louie, A. D. Zelenetz, J. P. O'Brien, C. Moskowitz, et al. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide Ann. Onc., October 1, 2004; 15(10): 1495 - 1503. [Abstract] [Full Text] [PDF] M. Voulgarelis, S. Giannouli, D. Anagnostou, and A. G. Tzioufas Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas Rheumatology, August 1, 2004; 43(8): 1050 - 1053. [Abstract] [Full Text] [PDF] D. Aguiar Bujanda, U. Bohn Sarmiento, J. Aguiar Morales, J. Bolanos-Meade, Y. Herishanu, A. Zomas, A. Skandalis, and N. Milpied Intensive Therapy for Aggressive Lymphoma N. Engl. J. Med., July 1, 2004; 351(1): 98 - 100. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020